

betic nephropathy[J]. *Acta Diabetol*, 2020, 57(11):1327-1335.

[2] Zhang L, Zhao SQ, Zhu YF. Long noncoding RNA growth arrest-specific transcript 5 alleviates renal fibrosis in diabetic nephropathy by downregulating matrix metalloproteinase 9 through recruitment of enhancer of zeste homolog 2 [J]. *FASEB J*, 2020, 34(2):2703-2714.

[3] Iiya M, Hikika H, Yoshikawa H, et al. Clinical outcomes after endovascular therapy among hemodialysis patients with peripheral artery disease stratified by the primary kidney disease[J]. *Ann Vasc Surg*, 2021, 73(1):197-204.

[4] Boyce JM, Dumigan DG, Havill NL, et al. A multi-center outbreak of *Candida tropicalis* bloodstream infections associated with contaminated hemodialysis machine prime buckets[J]. *Am J Infect Control*, 2021, 49(8):1008-1013.

[5] Irani S, Salajegheh A, Gopalan V, et al. Expression profile of endothelin 1 and its receptor endothelin receptor A in papillary thyroid carcinoma and their correlations with clinicopathologic characteristics[J]. *Ann Diagn Pathol*, 2014, 18(2):43-48.

[6] 瞿介明, 施毅. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)的更新与解读[J]. *中华结核和呼吸杂志*, 2018, 41(4):244-246.

[7] 潘拓方, 孙群群, 王彤瑞. 参芪固肾汤对糖尿病肾病患者肾功能血清炎症因子水平及血液流变学指标的影响[J]. *光明中医*, 2022, 37(17):3070-3072.

[8] 郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.

[9] Weinhandl ED, Gibertson DT, Collins AJ. Mortality, hospitalization, and technique failure in daily home hemodialysis and matched peritoneal dialysis patients; a matched cohort study[J]. *Am J Kidney Dis*, 2019, 67(1):98-110.

[10] 张婷, 刘丹, 孟静, 等. IL-10、SP-D 基因多态性与糖尿病肾病血液透析肺部感染易感性的关联[J]. *中华医院感染学杂志*, 2022, 32(22):3408-3413.

[11] Eisa NH, Khodir AE, El-Sherbiny M, et al. Phenethyl isothiocyanate attenuates diabetic nephropathy via modulation of glycaemic/oxidative/inflammatory signaling in diabetic rats[J]. *Biomed Pharmacother*, 2021, 142(1):111666.

[12] 刘天生. 某院 159 例糖尿病肾病患者血液透析致肺部感染的危险因素分析及其干预对策[J]. *抗感染药学*, 2019, 16(4):632-634.

[13] Vincent JL, Russell JA, Jacob M, et al. Albumin administration in the acutely ill: what is new and where next? [J]. *Crit Care*, 2019, 18(4):231.

[14] 丁仁华, 宣建宗, 吴亮亮, 等. 缙沙坦联合参芪固肾汤对糖尿病肾病患者的蛋白尿及 hs-CRP、IL-6 的干预作用[J]. *中医中西医结合肾病杂志*, 2023, 24(2):151-153.

[15] 孙伟, 王旭方. 糖尿病肾病合并感染的诊断与中医结合治疗[J]. *中华肾病研究电子杂志*, 2013, 2(4):177-182.

【收稿日期】 2023-04-13 【修回日期】 2023-07-02



(上接 1095 页)

[7] 金璐, 丁芳芳, 胡丹. 血清 CRP、WBC、PCT、CD64 指数联合检验在妇科感染性疾病中的诊断价值[J]. *中国现代药物应用*, 2022, 16(17):86-89.

[8] 孙昊轩, 李菁菁, 崔京京, 等. 口腔颌面部间隙感染炎症性介质表达及其联合检测诊断效能[J]. *中华医院感染学杂志*, 2022, 32(13):2029-2033.

[9] Lazenby GB, Soper DE. Prevention, diagnosis, and treatment of gynecologic surgical site infections [J]. *Obstet Gynecol Clin North Am*, 2010, 37(3):379-386.

[10] 郑大梅, 陈欧. 妇科术后切口感染危险因素的 logistic 回归分析[J]. *中华医院感染学杂志*, 2013, 23(5):1071-1072.

[11] 黎丽. 术后切口感染手术室相关危险因素的多元 Logistic 回归分析及干预[J]. *吉林医学*, 2020, 41(9):2288-2290.

[12] 刘永利. 经腹子宫肌瘤剥除术临床观察[J]. *中华肿瘤防治杂志*, 2016, 23(S2):244-245.

[13] Saadatnia G, Saremi S, Salehian B, et al. Uterine leiomyoma and reproductive tract infections detected by polymerase chain reaction[J]. *Iran J Pathol*, 2019, 14(1):33-40.

[14] Lemiech-mirowska E, Kier snowska ZM, Michalkiewicz M, et al. Nosocomial infections as one of the most important problems of healthcare system [J]. *Ann Agric Environ Med*, 2021, 28(3):361-366.

[15] He X, Li DR, Cui C, et al. Clinical significance of serum MCP-1 and VE-cadherin levels in patients with acute cerebral infarction [J]. *Eur Rev Med Pharmacol Sci*, 2017, 21(4):804-808.

【收稿日期】 2023-04-05 【修回日期】 2023-07-01

- Infect Dis, 2018, 18(1):13.
- [29] Motevaseli E, Azam R, Akrami SM, et al. The effect of *Lactobacillus crispatus* and *Lactobacillus rhamnosus* culture supernatants on expression of autophagy genes and HPV E6 and E7 oncogenes in the hela cell line [J]. Cell J, 2016, 17(4):601-607.
- [30] Bonner K, Banura C, Basta NE. HPV vaccination strategies targeting hard-to-reach populations: Out-of-school girls in LMICs [J]. Vaccine, 2018, 36(2):191-193.
- [31] Campisciano G, Iebba V, Zito G, et al. Lactobacillus iners and gasseri, prevotella bivia and HPV belong to the microbiological signature negatively affecting human reproduction [J]. Microorganisms, 2020, 9(1):39.
- [32] Ikeda Y, Uemura Y, Asai-Sato M, et al. Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for the treat-

- ment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study) [J]. Jpn J Clin Oncol, 2019, 49(9):877-880.
- [33] Mora-Palma JC, Rodriguez-Oliver AJ, Navarro-Mari JM, et al. Emergent genital infection by *Leptotrichia trevisanii* [J]. Infection, 2019, 47(1):111-114.
- [34] Mougeot JC, Beckman MF, Langdon HC, et al. *Haemophilus pittmaniae* and *Leptotrichia* spp. constitute a multi-marker signature in a cohort of human papillomavirus-positive head and neck cancer patients [J]. Front Microbiol, 2021, 12:794546.
- [35] 马啸, 蔡慧华, 何彦, 等. 复发性外阴阴道假丝酵母菌病患者阴道微生物的物种组成及其动态变化 [J]. 南方医科大学学报, 2017, 37(2):192-198.

【收稿日期】 2023-04-05 【修回日期】 2023-06-20

(上接 1004 页)

#### 【参考文献】

- [1] Hussain Z, Zhu J, Ma X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug [J]. Drug Metab Dispos, 2021, 49(8):679-682.
- [2] Zhao H, Si ZH, Li MH, et al. Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a (1)H NMR based metabolomics approach [J]. Toxicol Res (Camb), 2017, 6(1):17-29.
- [3] Chopyk DM, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders [J]. Gastroenterology, 2020, 159(3):849-863.
- [4] Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy [J]. J Hepatol, 2020, 72(3):558-577.
- [5] Gong S, Lan T, Zeng L, et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice [J]. J Hepatol, 2018, 69(1):51-59.
- [6] Sun Y, Cong L, Yang S, et al. Moxifloxacin induced liver injury by causing lachnospiraceae deficiency and interfering with butyric acid production through gut-liver axis [J]. Dis Markers, 2022, 2022:9302733.
- [7] Tilg H, Adolph T E, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications [J]. Cell Metab, 2022, 34(11):1700-1718.
- [8] Bajaj J S. Alcohol, liver disease and the gut microbiota [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4):235-246.
- [9] Plaza-Diaz J, Solis-Urra P, Rodriguez-Rodriguez F, et al. The gut barrier, intestinal microbiota, and liver disease: Molecular mechanisms and strategies to manage [J]. Int J Mol Sci, 2020, 21(21):8351.
- [10] 杨璐铭, 郝金奇, 王林, 等. 基于 16S rDNA 测序技术分析利福平致大鼠肝损伤中肠道菌群变化特征 [J]. 安徽医科大学学报, 2022, 57(9):1469-1474.
- [11] Zhao T, Wang H, Liu Z, et al. Recent perspective of lactobacillus in reducing oxidative stress to prevent disease [J]. Antioxidants (Basel), 2023, 12(3):769.
- [12] Wu S, Xia Y, Lv X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients [J]. J Gastroenterol Hepatol, 2015, 30(3):540-545.
- [13] Cani P D, Depommier C, Derrien M, et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms [J]. Nat Rev Gastroenterol Hepatol, 2022, 19(10):625-637.
- [14] Saito Z, Kaneko Y, Kinoshita A, et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis [J]. BMC Infect Dis, 2016, 16(1):668.
- [15] De Vos W M, Tilg H, Van Hul M, et al. Gut microbiome and health, mechanistic insights [J]. Gut, 2022, 71(5):1020-1032.
- [16] Li X, Liu Y, Guo X, et al. Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury [J]. Eur J Clin Nutr, 2021, 75(8):1227-1236.

【收稿日期】 2023-04-04 【修回日期】 2023-06-20